In a significant pharmaceutical patent enforcement action, Intra-Cellular Therapies, Inc. filed suit against MSN Laboratories Private, Ltd. in the District of New Jersey on March 28, 2024, asserting nine patents covering CAPLYTA® (lumateperone) capsules across three dosage strengths (10.5 mg, 21 mg, and 42 mg). The case, docketed as 3:24-cv-04325, was administratively closed after just 130 days when the court consolidated it into lead Civil Action No. 24-4264 alongside six related ANDA proceedings — a procedural consolidation ordered July 16, 2024, reflecting the complexity of multi-defendant Hatch-Waxman litigation.

For IP professionals and patent attorneys active in the pharmaceutical space, this consolidation signals that CAPLYTA®’s expansive patent estate — spanning composition, formulation, and method-of-treatment claims — is now subject to coordinated challenge across multiple generic filers simultaneously. The outcome of the lead consolidated action will carry significant consequences for Intra-Cellular Therapies’ market exclusivity and for generic entrants seeking to launch competing lumateperone products, making this a closely watched ANDA battleground.

Case Overview

The Parties

The Patents at Issue

The nine asserted patents cover multiple aspects of lumateperone (ITI-007), the active pharmaceutical ingredient in CAPLYTA®. Collectively, these patents protect the compound itself, specific salt and polymorph forms, pharmaceutical formulations at defined dosage strengths, and methods of treating conditions such as schizophrenia and bipolar depression using lumateperone. The patent estate includes a reissue patent (USRE048839E) alongside eight utility patents, reflecting Intra-Cellular Therapies’ layered strategy to defend the CAPLYTA® franchise across different claim types and expiration dates.

• • US11026951B2
• • US10695345B2
• • US10960009B2
• • US9956227B2
• • US11690842B2
• • US11753419B2
• • US11052084B2
• • US11806348B2
• • USRE048839E

Legal Representation

Plaintiff Counsel: Walsh Pizzi O’Reilly Falanga LLP (lead: Katelyn O’Reilly)
Defendant Counsel: MIDLIGE RICHTER LLC (lead: James S. Richter)

Litigation Timeline & Procedural History

This case was filed on March 28, 2024, in the United States District Court for the District of New Jersey — the dominant venue for Hatch-Waxman ANDA litigation, chosen for its established procedural familiarity with pharmaceutical patent disputes, proximity to the pharma industry corridor, and experienced judiciary. As a first-instance district court proceeding, the case was positioned for full Markman claim construction, discovery, and potential trial on infringement and validity of all nine asserted patents.

The case closed after 130 days without a merits determination, as the court administratively consolidated it with six related actions into lead case No. 24-4264 pursuant to a July 16, 2024 consolidation order. This rapid procedural resolution is typical in Hatch-Waxman multi-defendant scenarios where multiple generic filers submit overlapping ANDAs, prompting the court to streamline proceedings. Notably, all parties expressly reserved their rights to seek separate trials under Federal Rule of Civil Procedure 42(b), preserving the possibility of individualized proceedings on damages or specific infringement theories if the consolidated action advances to trial.

The Verdict & Legal Analysis

Outcome

No merits determination was reached in Civil Action No. 3:24-cv-04325. The case was administratively closed on August 5, 2024, pursuant to the court’s consolidation order, which designated Civil Action No. 24-4264 as the lead action for all seven related proceedings. No damages were awarded, no injunctive relief was separately ordered in this action, and no infringement or validity findings were entered — all substantive issues remain pending in the consolidated lead proceeding.

Verdict Cause Analysis

The administrative closure arose from procedural consolidation rather than any substantive ruling on the merits of the infringement claims:

• The court entered a consolidation order on July 16, 2024, merging seven related ANDA infringement actions — including this case — under a single lead docket (Civil Action No. 24-4264) to promote judicial efficiency and consistent adjudication of overlapping patent claims.
• The Clerk was directed to list all local counsel of record from the seven consolidated actions in the lead case and route all future filings through Civil Action No. 24-4264, effectively extinguishing the independent procedural life of this action.
• All parties explicitly reserved their rights to request separate joint or individual trials pursuant to Federal Rule of Civil Procedure 42(b), acknowledging that consolidation for pretrial purposes does not necessarily merge the cases for trial.
• The basis of termination — case consolidation — reflects a standard Hatch-Waxman multi-defendant management technique, not a finding of non-infringement, invalidity, or dismissal on the merits.

Legal Significance

1. 1. The consolidation of seven ANDA actions involving CAPLYTA® signals that multiple generic manufacturers filed overlapping Paragraph IV certifications simultaneously, a pattern that typically intensifies claim construction disputes and may accelerate the 30-month stay timeline applicable across all challengers.
2. 2. Because all parties reserved Rule 42(b) rights, the consolidated proceeding may ultimately bifurcate into separate trials — particularly relevant if different generic defendants assert distinct invalidity theories or non-infringement positions tied to their specific ANDA formulations.
3. 3. The breadth of the asserted patent estate — nine patents including a reissue patent covering compound, formulation, and method-of-treatment claims — creates substantial litigation complexity in the lead consolidated action, as claim construction rulings on any single patent will carry precedential weight across all seven defendant proceedings.

Strategic Takeaways

For Patent Attorneys:

• Monitor the lead consolidated action (No. 24-4264) for Markman hearing dates and claim construction orders, as rulings on the nine asserted patents will bind all seven consolidated defendants and inform validity and infringement strategy across the entire CAPLYTA® patent dispute.
• Assess whether your generic client’s specific ANDA formulation supports a viable non-infringement position distinct from co-defendants — if so, file early motions to preserve separate trial rights under Rule 42(b) before the consolidated schedule is locked.
• Evaluate IPR petition opportunities against the weaker members of the nine-patent estate, particularly the reissue patent USRE048839E, where reissue-specific prosecution history may limit claim scope and provide discrete invalidity arguments.
• Track the 30-month regulatory stay expiration dates across all nine patents and coordinate with FDA counsel to understand the ANDA approval timeline, as tentative approvals may issue during litigation if stay periods lapse before final judgment.

For IP Professionals:

• Map Intra-Cellular Therapies’ full CAPLYTA® patent estate — including the nine asserted patents and any related continuations or divisionals — to identify the true exclusivity horizon and assess licensing or settlement value in the lead consolidated proceeding.
• Implement a litigation watch on Civil Action No. 24-4264 to receive real-time updates on claim construction, expert discovery, and any summary judgment motions that will define the scope of CAPLYTA® patent protection for competitive intelligence purposes.

For R&D Teams:

• If developing lumateperone-based or lumateperone-adjacent formulations, conduct a freedom-to-operate analysis against all nine asserted patents — particularly the method-of-treatment claims — before advancing candidates into clinical or regulatory development.
• Consider design-around opportunities focused on alternative salt forms, polymorphs, or dosing regimens not covered by the asserted composition and formulation claims, particularly given the layered claim structure spanning nine distinct patents.